Pharmaceuticals

Pharmaceuticals

Reading the Blood: What Etcamah's Approval Means for Breast Cancer and the Liquid Biopsy Era

AstraZeneca's Etcamah became the first FDA-approved cancer therapy triggered by a blood test detecting resistance before imaging shows progression. The approval rewrites how oncologists think about treatment switching in HR-positive breast cancer.

Biotechnology

A Name for the Nameless: What Zanvastro's Approval Means for Alexander Disease and RNA Medicine

The FDA's approval of Zanvastro marks the first treatment ever approved for Alexander disease, signaling a broader shift in how RNA-targeted therapies can address ultra-rare neurological conditions.

Pharmaceuticals

The Second Wave: Why GSK's mRNA Flu Vaccine Push Could Reshape a Market Moderna Just Opened

GSK is advancing an mRNA flu vaccine that targets both hemagglutinin and neuraminidase into Phase 3, a more ambitious dual-antigen approach than Moderna's recently approved mFlusiva. Here is what the science means and why it matters.

Pharmaceuticals

Thirty Years in the Making: What the FDA's BESREMi Approval Means for Essential Thrombocythemia

The FDA's approval of BESREMi marks the first new therapy for essential thrombocythemia in nearly 30 years, signaling a shift toward disease-modifying treatments that target the molecular drivers of this rare blood cancer.

Pharmaceuticals

The Last Frontier in Cardiology: Why the Lp(a) Drug Race Could Rewrite Heart Disease Prevention

Novartis, Amgen, and Eli Lilly are racing to address Lp(a), a genetic cardiovascular risk factor affecting 1 in 5 people with no approved treatment. The first pivotal outcomes data could arrive within weeks.

Biotechnology

The Undruggable Made Druggable: What Rasonque's FDA Approval Means for Pancreatic Cancer and the RAS Era

The FDA's approval of Rasonque marks a watershed moment in oncology—the first therapy to directly target RAS, ending three decades of failed attempts to drug one of cancer's most intractable targets.

Pharmaceuticals

Fixing the Wiring: What Takeda's Orzeyful Approval Means for Narcolepsy and the Orexin Era

Takeda's FDA approval of Orzeyful marks a paradigm shift in narcolepsy treatment—the first medicine to directly target orexin deficiency rather than manage symptoms.

Biotechnology

Beyond GLP-1: Roche's $2.3B Bet on Muscle-Sparing Obesity Science

Roche commits $2.3 billion to Hanmi's UCN2 obesity drug candidate, signaling a strategic shift toward muscle-preserving mechanisms beyond GLP-1 agonists.

Pharmaceuticals

Alzheimer's Treatment Comes Home: What the FDA's Lecanemab Subcutaneous Approval Really Changes

The FDA approved a subcutaneous starting dose of lecanemab, allowing Alzheimer's patients to begin treatment at home via weekly self-injection—removing a major access barrier to this disease-modifying therapy.

Biotechnology

One Gene, One Dose: What Ultragenyx's Genglycos Approval Means for Rare Metabolic Disease and the Gene Therapy Era

The FDA's accelerated approval of Ultragenyx's Genglycos marks the first gene therapy for glycogen storage disease type Ia, signaling a new era in treating rare metabolic diseases at their genetic root.

Biotechnology

The Vaccine That Learned From COVID: What Moderna and Merck's Phase 3 Win Means for Cancer Medicine

Moderna and Merck's personalized mRNA cancer vaccine intismeran autogene has succeeded in its first Phase 3 trial in melanoma, marking the first late-stage win for any mRNA cancer vaccine and raising profound questions about the future of oncology and the mRNA platform itself.

Biotechnology

The Keytruda Problem: What AstraZeneca's Volrustomig Failure Reveals About the Bispecific Antibody Race in Lung Cancer

AstraZeneca discontinues Phase 3 trial of volrustomig, its PD-1/CTLA-4 bispecific antibody in lung cancer, revealing structural challenges in displacing Keytruda and diverging fortunes in the bispecific antibody race.